Rodney P. Rocconi, M.D., joined Mitchell Cancer Institute (MCI) as a physician-scientist in the Gynecologic Oncology Service in 2007. He was the first MCI Abraham A. Mitchell Cancer Research Scholar. He specializes in the management of cancers of the ovary, uterus, cervix and lower genital tract. As the Associate Director for Clinical Research, Dr. Rocconi provides leadership and medical expertise to the clinical trials department, reviews and designs clinical research protocols, evaluates safety and efficacy data, analyzes and summarizes data for presentation to regulatory agencies, and provides strategic guidance on non-regulatory clinical trial plans. He is the recipient of the Gynecologic Cancer Foundation Ovarian Cancer Research Award and the Gynecologic Oncology Young Investigator Research Award. Dr. Rocconi also serves as a scientific expert reviewer for the U.S. Department of Defense Ovarian Cancer Research Program.
USA Health has a comprehensive biomedical research program that spans a wide range of clinical, basic and translational research. At the Mitchell Cancer Institute, our physicians and scientific investigators are searching for breakthrough discoveries to improve the lives of cancer patients.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma (LEAP-001)
Patients with Endometrial Carcinoma
A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors
Treatment for Advanced Solid Tumors
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors
Treatment for Solid Tumors
A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034 (anti–PD-1) as a Monotherapy or Combination Therapy with AGEN1884 (anti-CTLA4) or with Placebo in Women with Recurrent Cervical Cancer (Second Line) - RaPiDS
Treatment for Cervical Cancer
A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer.
Treatment for Uterine / Vaginal Cancer
African-American patients with advanced ovarian cancer were found to have a pre-existing immune response linked to worse survival rates compared with their white counterparts, according to research led by Dr. Rodney P. Rocconi, a gynecologic oncologist and interim director of the USA Health Mitchell Cancer Institute.
